451 related articles for article (PubMed ID: 29229609)
1. Recent advances in pre-exposure prophylaxis for HIV.
Desai M; Field N; Grant R; McCormack S
BMJ; 2017 Dec; 359():j5011. PubMed ID: 29229609
[TBL] [Abstract][Full Text] [Related]
2. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
Adams JL; Shelley K; Nicol MR
Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
[TBL] [Abstract][Full Text] [Related]
3. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM
JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128
[TBL] [Abstract][Full Text] [Related]
4. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
McCormack S; Dunn DT; Desai M; Dolling DI; Gafos M; Gilson R; Sullivan AK; Clarke A; Reeves I; Schembri G; Mackie N; Bowman C; Lacey CJ; Apea V; Brady M; Fox J; Taylor S; Antonucci S; Khoo SH; Rooney J; Nardone A; Fisher M; McOwan A; Phillips AN; Johnson AM; Gazzard B; Gill ON
Lancet; 2016 Jan; 387(10013):53-60. PubMed ID: 26364263
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
[TBL] [Abstract][Full Text] [Related]
6. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.
Murewanhema G; Malisheni M; Takah NF
Pan Afr Med J; 2021; 38():308. PubMed ID: 34178226
[TBL] [Abstract][Full Text] [Related]
8. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.
Trang TP; Dong BJ; Kojima N; Klausner JD
Expert Opin Drug Saf; 2016 Sep; 15(9):1287-94. PubMed ID: 27391203
[TBL] [Abstract][Full Text] [Related]
9. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
[TBL] [Abstract][Full Text] [Related]
10. Piloting a partially self-financed mode of human immunodeficiency virus pre-exposure prophylaxis delivery for men who have sex with men in Hong Kong.
Lee SS; Kwan TH; Wong NS; Lee KCK; Chan DPC; Lam TTN; Lui GCY
Hong Kong Med J; 2019 Oct; 25(5):382-391. PubMed ID: 31619578
[TBL] [Abstract][Full Text] [Related]
11. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
[TBL] [Abstract][Full Text] [Related]
12. The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.
Solomon MM; Schechter M; Liu AY; McMahan VM; Guanira JV; Hance RJ; Chariyalertsak S; Mayer KH; Grant RM;
J Acquir Immune Defic Syndr; 2016 Mar; 71(3):281-6. PubMed ID: 26413853
[TBL] [Abstract][Full Text] [Related]
13. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
Traeger MW; Cornelisse VJ; Asselin J; Price B; Roth NJ; Willcox J; Tee BK; Fairley CK; Chang CC; Armishaw J; Vujovic O; Penn M; Cundill P; Forgan-Smith G; Gall J; Pickett C; Lal L; Mak A; Spelman TD; Nguyen L; Murphy DA; Ryan KE; El-Hayek C; West M; Ruth S; Batrouney C; Lockwood JT; Hoy JF; Hellard ME; Stoové MA; Wright EJ;
JAMA; 2019 Apr; 321(14):1380-1390. PubMed ID: 30964528
[TBL] [Abstract][Full Text] [Related]
14. Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions.
Hodges-Mameletzis I; Fonner VA; Dalal S; Mugo N; Msimanga-Radebe B; Baggaley R
Drugs; 2019 Aug; 79(12):1263-1276. PubMed ID: 31309457
[TBL] [Abstract][Full Text] [Related]
15. An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.
Dolling DI; Desai M; McOwan A; Gilson R; Clarke A; Fisher M; Schembri G; Sullivan AK; Mackie N; Reeves I; Portman M; Saunders J; Fox J; Bayley J; Brady M; Bowman C; Lacey CJ; Taylor S; White D; Antonucci S; Gafos M; McCormack S; Gill ON; Dunn DT; Nardone A;
Trials; 2016 Mar; 17():163. PubMed ID: 27013513
[TBL] [Abstract][Full Text] [Related]
16. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
[TBL] [Abstract][Full Text] [Related]
17. Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.
Landovitz RJ; Beymer M; Kofron R; Amico KR; Psaros C; Bushman L; Anderson PL; Flynn R; Lee DP; Bolan RK; Jordan WC; Tseng CH; Dierst-Davies R; Rooney J; Wohl AR
J Acquir Immune Defic Syndr; 2017 Dec; 76(5):501-511. PubMed ID: 28902074
[TBL] [Abstract][Full Text] [Related]
18. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study.
Hoornenborg E; Coyer L; Achterbergh RCA; Matser A; Schim van der Loeff MF; Boyd A; van Duijnhoven YTHP; Bruisten S; Oostvogel P; Davidovich U; Hogewoning A; Prins M; de Vries HJC;
Lancet HIV; 2019 Jul; 6(7):e447-e455. PubMed ID: 31178284
[TBL] [Abstract][Full Text] [Related]
19. Study on Pre-Exposure Prophylaxis Regimens among Men Who Have Sex with Men: A Prospective Cohort Study.
Wu D; Tao H; Dai J; Liang H; Huang A; Zhong X
Int J Environ Res Public Health; 2019 Dec; 16(24):. PubMed ID: 31818006
[No Abstract] [Full Text] [Related]
20. Importance of early identification of PrEP breakthrough infections in a generalized HIV epidemic: a case report from a PrEP demonstration project in South Africa.
Naicker CL; Mansoor LE; Dawood H; Naidoo K; Singo D; Matten D; Williamson C; Abdool Karim Q
BMC Infect Dis; 2020 Jul; 20(1):532. PubMed ID: 32698772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
